Navigation

Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566]

Masitinib for the treatment of locally advanced or metastatic pancreatic cancer

Status: In development
Expected date of issue: TBC
Process: STA
Topic area:
 

NICE project team

Technical Lead: Rosemary Lovett
Communications manager: Alice Law
Project manager:

Bijal Joshi

Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 12 November 2013
1st appraisal committee meeting: TBC
2nd appraisal committee meeting TBC
Top


 

Consultees and commentators

To be confirmed

Top


 

Project history

Date Notes
04 February 2014

Please note that the manufacturer has informed NICE that they will not provide an evidence submission on the date requested, therefore we are temporarily suspending the appraisal whilst we consider the next steps.

Therefore, the Committee Meeting will note take place 23 April 2014

03 May 2013 Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations.
Top


 

Key documents

This page was last updated: 28 February 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.